Stock listing
PASG Stock Price, News, Filings & Events — Passage Bio, Inc.
Selected listing: PASG · NASDAQ · USD · US
This page tracks Passage Bio, Inc.'s PASG:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following PASG:NASDAQ. PASG:NASDAQ is the stock-level entry point for investors researching Passage Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Passage Bio, Inc. is a public company traded under the ticker PASG in the American market. The company has a market capitalization of approximately $15.5 million. Passage Bio focuses on developing gene therapies for neurological diseases, aiming to address significant unmet medical needs in this area.
- Ticker
- PASG:NASDAQ
- Asset type
- Stock
- Market cap
- $16.1M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Passage Bio, Inc. PASG:NASDAQ stock context
This page tracks Passage Bio, Inc.'s PASG:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following PASG:NASDAQ. PASG:NASDAQ is the stock-level entry point for investors researching Passage Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Passage Bio, Inc. is a public company traded under the ticker PASG in the American market. The company has a market capitalization of approximately $15.5 million. Passage Bio focuses on developing gene therapies for neurological diseases, aiming to address significant unmet medical needs in this area.
Latest news from Passage Bio, Inc.
Passage Bio and Remix Therapeutics Announce Merger Agreement
June 25, 2026
Passage Bio and Remix Therapeutics Announce Merger Agreement
June 24, 2026
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
April 20, 2026
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
March 3, 2026
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
November 10, 2025
Passage Bio, Inc. earnings calls
Passage Bio, Inc. (PASG) Q4 2022 Earnings Call
March 6, 2023 · Replay with transcript and chapters
Passage Bio, Inc. (PASG) Q3 2022 Earnings Call
November 10, 2022 · Replay with transcript and chapters
Passage Bio, Inc. (PASG) Q2 2022 Earnings Call
August 4, 2022 · Replay with transcript and chapters
Passage Bio, Inc. (PASG) Q1 2022 Earnings Call
May 16, 2022 · Replay with transcript and chapters
Passage Bio, Inc. (PASG) Q4 2021 Earnings Call
March 3, 2022 · Replay with transcript and chapters
Passage Bio, Inc. (PASG) Q2 2021 Earnings Call
August 5, 2021 · Replay with transcript and chapters
Research Passage Bio, Inc.
Passage Bio, Inc. investor report
Review AI stock analysis and investor report context for PASG:NASDAQ.
Passage Bio, Inc. company profile
View the public company page for Passage Bio, Inc. on 6ix.
Passage Bio, Inc. news
Read company news and market updates connected to Passage Bio, Inc..
Passage Bio, Inc. investor events
Find investor webinars, events, and replay context for Passage Bio, Inc..